SCHEMBL4371172

SCHEMBL4371172

O=C1CSC(c2cccc(Cl)c2)c2cc(C(=O)c3ccc(Cl)cc3)ccc2N1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.55
MAPT P10636 3/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
CASP1 P29466 1/20 0.55
CYP2C19 P33261 1/20 0.55
RECQL P46063 1/20 0.55
SLC8B1 Q6J4K2 1/20 0.55
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ATM Q13315 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PPARG P37231 1/20 0.40
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
GAA P10253 1/20 0.37
MDM2 Q00987 2/20 0.36
FNTA P49354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30006499 0.81 LMNA (0.58) TP53MAPTMEN1KMT2AATM
SCHEMBL1538402 0.81 LMNA (0.58) TP53MAPTMEN1KMT2AATM
SCHEMBL7701639 0.74 TP53 (0.51) TP53MAPTMEN1KMT2AATM
SCHEMBL5555500 0.74 MEN1 (0.47) TP53MAPTTSHRMEN1KMT2A
SCHEMBL4373631 0.72 FNTA (0.59) TP53MAPTCYP1A2CYP2C9ALOX15
SCHEMBL4371953 0.72 FNTA (0.47) TP53MAPTCYP1A2CYP2C9ALOX15
SCHEMBL5657981 0.71 LMNA (0.53) TP53MAPTRECQLMEN1KMT2A
SCHEMBL31071906 0.71 TP53 (1.00) TP53MAPTCYP1A2CYP2C9ALOX15
SCHEMBL869274 0.71 TP53 (1.00) TP53MAPTCYP1A2CYP2C9ALOX15
SCHEMBL10044117 0.70 TP53 (0.79) TP53MAPTCYP1A2CYP2C9ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339709-B1 FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
US-7153958-B2 Farnesyl transferase inhibiting benzoheterocyclic derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-26 US disclosed
US-20040034218-A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2004-02-19 US disclosed
EP-1339709-A1 FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-09-03 EP disclosed
WO-2002042296-A1 FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034218-A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives FNTA, FNTB, RCE1 TP53 2218/4885MAPT 3857/4885CYP1A2 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.